Shivan Sivakumar
Overview
Explore the profile of Shivan Sivakumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease
Mato Prado M, Puik J, Castellano L, Lopez-Jimenez E, Liu D, Meijer L, et al.
Exp Hematol Oncol
. 2023 Dec;
12(1):101.
PMID: 38041102
Differentiating between pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) is crucial for the appropriate course of treatment, especially with advancements in the role of neoadjuvant chemotherapies for PDAC, compared to...
12.
Johnston A, Sivakumar S, Zhou Y, Funston G, Bradley S
Br J Gen Pract
. 2023 Nov;
73(737):534-535.
PMID: 38035808
No abstract available.
13.
Spiers L, Gray M, Lyon P, Sivakumar S, Bekkali N, Scott S, et al.
BMC Cancer
. 2023 Sep;
23(1):896.
PMID: 37741968
Background: The dense stroma of pancreatic ductal adenocarcinomas is a major barrier to drug delivery. To increase the local drug diffusion gradient, high doses of chemotherapeutic agent doxorubicin can be...
14.
Chouari T, La Costa F, Merali N, Jessel M, Sivakumar S, Annels N, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686543
Pancreatic ductal adenocarcinoma (PDAC) accounts for up to 95% of all pancreatic cancer cases and is the seventh-leading cause of cancer death. Poor prognosis is a result of late presentation,...
15.
Heij L, Bednarsch J, Tan X, Rosin M, Appinger S, Reichel K, et al.
Cells
. 2023 Mar;
12(6).
PMID: 36980192
: The tumor microenvironment (TME) in cholangiocarcinoma (CCA) influences the immune environment. Checkpoint blockade is promising, but reliable biomarkers to predict response to treatment are still lacking. : The levels...
16.
Jainarayanan A, Mouroug-Anand N, Arbe-Barnes E, Bush A, Bashford-Rogers R, Frampton A, et al.
iScience
. 2023 Mar;
26(4):106324.
PMID: 36968070
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest types of cancer and has a 5-year survival of less than 8% owing to its complex biology. As PDAC is refractory to...
17.
Tan P, Garriga C, Clift A, Liao W, Patone M, Coupland C, et al.
Gut
. 2022 Jun;
72(3):512-521.
PMID: 35760494
Objective: Prior studies identified clinical factors associated with increased risk of pancreatic ductal adenocarcinoma (PDAC). However, little is known regarding their time-varying nature, which could inform earlier diagnosis. This study...
18.
Bradley S, Hemphill S, Markham S, Sivakumar S
BMJ
. 2022 Jun;
377:e070876.
PMID: 35760419
No abstract available.
19.
Sivakumar S, Rocha F, Heij L
Hepatobiliary Surg Nutr
. 2022 Jun;
11(3):422-424.
PMID: 35693389
No abstract available.
20.
Madge O, Brodey A, Bowen J, Nicholson G, Sivakumar S, Bottomley M
J Clin Med
. 2022 May;
11(9).
PMID: 35566700
The COVID-19 pandemic has hugely disrupted healthcare provision, including oncology services. To evaluate the effects of the pandemic on referral routes leading to diagnosis, treatments, and prognosis in patients with...